Olema reports preliminary cash >$500M as of Dec 31, 2025

Olema Pharmaceuticals, Inc.

Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).
No other financial results disclosed; annual 10-K filing pending.
Investor presentation posted on company website as of January 12, 2026.
Cash position provides runway for ongoing breast cancer pipeline development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.